ClinicalTrials.gg
Sign In

Myelodysplastic Syndromes clinical trials

The registry lists 1,997 studies for Myelodysplastic Syndromes across more than 10 countries. 324 are recruiting or about to start. 698 of them are mainly about Myelodysplastic Syndromes (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12. Counting its 3 narrower conditions too, such as Hemoglobinuria, Paroxysmal: 2,220 studies, 371 open.

ClinicalTrials.gov finds 2,695 studies for Myelodysplastic Syndromes. How that becomes 1,996 here

This page counts the studies the registry files under Myelodysplastic Syndromes, and those it files under no condition that list Myelodysplastic Syndromesthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

  1. 2,695Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −220Filed under a narrower condition, counted on its own pageHemoglobinuria, Paroxysmal 172 · Anemia, Refractory, with Excess of Blasts 41 · Anemia, Refractory 7
  3. −205List Myelodysplastic Syndromes as a condition, but the registry did not file them under itMost often written as “Previously Treated Myelodysplastic Syndromes” (55), “de Novo Myelodysplastic Syndromes” (48), and “Secondary Myelodysplastic Syndromes” (41). The registry filed them under other conditions only, most often Leukemia, Myeloid, Acute (166) and Congenital Abnormalities (62).
  4. −274Match it another way121 name it in the title, 42 in a keyword, and 111 by a synonym or other text the search reads.
  5. 1,996The count on this page27 of them list Myelodysplastic Syndromes in their own words; the registry filed them under no condition.

Get an email when these change. Save the Myelodysplastic Syndromes studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed
974
Terminated
325
Recruiting
264
Active, not recruiting
133
Status unknown
131
Withdrawn
84

Phase

Phase 2
1,023
Phase 1
714
Phase 3
154
Phase 4
26
Early Phase 1
19

Where

United States
1,363
France
198
Germany
160
Italy
134
China
117
Canada
116

Who runs them

M.D. Anderson Cancer Center (146) · Fred Hutchinson Cancer Center (63) · National Cancer Institute (NCI) (52) · Memorial Sloan Kettering Cancer Center (50) · Celgene (45) · Masonic Cancer Center, University of Minnesota (42) · City of Hope Medical Center (41) · Novartis Pharmaceuticals (36)

What is being tested here

Drugs under test in Myelodysplastic Syndromes studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

DrugOpenPhase 3All
Fludarabine237148
Cyclophosphamide204126
Venetoclax17238
Azacitidine1312126
Busulfan12994
Melphalan12563
Cytarabine10359
Decitabine9675
Tacrolimus6044
Luspatercept6718

Drug classes tested here Antimetabolites 53 open · Alkylating agents 34 open · Tyrosine kinase inhibitors (TKIs) 16 open · Calcineurin inhibitors 8 open · JAK inhibitors 8 open

Coming up

30phase 3 studies under way
131studies finish main data collection within a year4 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 264 Myelodysplastic Syndromes studies recruiting now, 167 (63%) set no upper age limit and 70 (27%) stop at 75 or younger. 57 (22%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 17 (6%) take healthy volunteers.

Recruiting studies that take each age, of 264
AgeWomenMen
1041 (16%)41 (16%)
18252 (95%)252 (95%)
30250 (95%)250 (95%)
40246 (93%)246 (93%)
50244 (92%)244 (92%)
65244 (92%)244 (92%)
75218 (83%)218 (83%)
85183 (69%)183 (69%)

Across all 1,997 studies, recruiting or not: 30% stop at 75 or younger and 18% at 65; 26% take children; <1% are for women only and <1% for men only; 3% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Myelodysplastic Syndromes studies take

Of 279 phase 2 interventional studies under Myelodysplastic Syndromes, half reached primary completion within 66 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 152 mo31–86 · 219 studies44 mo30–72 · 84 studies52 mo35–90 · 135 studies
Phase 1/278 mo49–110 · 109 studies78 mo56–91 · 41 studies72 mo49–142 · 68 studies
Phase 266 mo40–104 · 279 studies40 mo30–62 · 52 studies76 mo44–116 · 227 studies
Phase 350 mo38–95 · 45 studies42 mo33–52 · 26 studies—
Interventional, no phase65 mo40–125 · 58 studies—66 mo33–125 · 57 studies
Observational84 mo34–… · 101 studies—96 mo51–… · 78 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 14, 2026.

Started recruiting6

Show 1 more

Results posted1

Stopped1

Newly registered5

Studies

Recruiting first, then most recently updated. Showing 50 of 1,997. Browse all 1,997 → or search them.